These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 21242980)
1. Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation. Yang Y; Tse AK; Li P; Ma Q; Xiang S; Nicosia SV; Seto E; Zhang X; Bai W Oncogene; 2011 May; 30(19):2207-18. PubMed ID: 21242980 [TBL] [Abstract][Full Text] [Related]
2. Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications. Zhao X; Sternsdorf T; Bolger TA; Evans RM; Yao TP Mol Cell Biol; 2005 Oct; 25(19):8456-64. PubMed ID: 16166628 [TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase 4 inhibits NF-κB activation by facilitating IκBα sumoylation. Yang Q; Tang J; Xu C; Zhao H; Zhou Y; Wang Y; Yang M; Chen X; Chen J J Mol Cell Biol; 2020 Jul; 12(12):933-945. PubMed ID: 32770227 [TBL] [Abstract][Full Text] [Related]
4. The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. Kirsh O; Seeler JS; Pichler A; Gast A; Müller S; Miska E; Mathieu M; Harel-Bellan A; Kouzarides T; Melchior F; Dejean A EMBO J; 2002 Jun; 21(11):2682-91. PubMed ID: 12032081 [TBL] [Abstract][Full Text] [Related]
5. Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Fu M; Wang C; Wang J; Zhang X; Sakamaki T; Yeung YG; Chang C; Hopp T; Fuqua SA; Jaffray E; Hay RT; Palvimo JJ; Jänne OA; Pestell RG Mol Cell Biol; 2002 May; 22(10):3373-88. PubMed ID: 11971970 [TBL] [Abstract][Full Text] [Related]
6. Androgen receptor corepressor-19 kDa (ARR19), a leucine-rich protein that represses the transcriptional activity of androgen receptor through recruitment of histone deacetylase. Jeong BC; Hong CY; Chattopadhyay S; Park JH; Gong EY; Kim HJ; Chun SY; Lee K Mol Endocrinol; 2004 Jan; 18(1):13-25. PubMed ID: 14576337 [TBL] [Abstract][Full Text] [Related]
7. Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers. Ren G; Zhang G; Dong Z; Liu Z; Li L; Feng Y; Su D; Zhang Y; Huang B; Lu J Int J Biochem Cell Biol; 2009 May; 41(5):1094-101. PubMed ID: 19013255 [TBL] [Abstract][Full Text] [Related]
8. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer. McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324 [TBL] [Abstract][Full Text] [Related]
9. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. Gaughan L; Logan IR; Cook S; Neal DE; Robson CN J Biol Chem; 2002 Jul; 277(29):25904-13. PubMed ID: 11994312 [TBL] [Abstract][Full Text] [Related]
10. Androgen receptor regulates nuclear trafficking and nuclear domain residency of corepressor HDAC7 in a ligand-dependent fashion. Karvonen U; Jänne OA; Palvimo JJ Exp Cell Res; 2006 Oct; 312(16):3165-83. PubMed ID: 16860317 [TBL] [Abstract][Full Text] [Related]
11. SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells. Zheng Z; Cai C; Omwancha J; Chen SY; Baslan T; Shemshedini L J Biol Chem; 2006 Feb; 281(7):4002-12. PubMed ID: 16361251 [TBL] [Abstract][Full Text] [Related]
12. SUMO-specific protease 1 modulates cadmium-augmented transcriptional activity of androgen receptor (AR) by reversing AR SUMOylation. Wu R; Cui Y; Yuan X; Yuan H; Wang Y; He J; Zhao J; Peng S Toxicol Lett; 2014 Sep; 229(2):405-13. PubMed ID: 25014244 [TBL] [Abstract][Full Text] [Related]
13. Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines. Fialova B; Smesny Trtkova K; Paskova L; Langova K; Kolar Z Oncol Rep; 2013 May; 29(5):2039-45. PubMed ID: 23503510 [TBL] [Abstract][Full Text] [Related]
14. Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation. Sutinen P; Rahkama V; Rytinki M; Palvimo JJ Mol Endocrinol; 2014 Oct; 28(10):1719-28. PubMed ID: 25127374 [TBL] [Abstract][Full Text] [Related]
15. Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus. Rytinki M; Kaikkonen S; Sutinen P; Paakinaho V; Rahkama V; Palvimo JJ Mol Cell Biol; 2012 Oct; 32(20):4195-205. PubMed ID: 22890844 [TBL] [Abstract][Full Text] [Related]
16. Androgen receptor signaling: mechanism of interleukin-6 inhibition. Jia L; Choong CS; Ricciardelli C; Kim J; Tilley WD; Coetzee GA Cancer Res; 2004 Apr; 64(7):2619-26. PubMed ID: 15059919 [TBL] [Abstract][Full Text] [Related]
17. Panobinostat reverses HepaCAM gene expression and suppresses proliferation by increasing histone acetylation in prostate cancer. Chen E; Liu N; Zhao Y; Tang M; Ou L; Wu X; Luo C Gene; 2022 Jan; 808():145977. PubMed ID: 34592353 [TBL] [Abstract][Full Text] [Related]
18. Class I HDAC inhibition stimulates cardiac protein SUMOylation through a post-translational mechanism. Blakeslee WW; Wysoczynski CL; Fritz KS; Nyborg JK; Churchill ME; McKinsey TA Cell Signal; 2014 Dec; 26(12):2912-20. PubMed ID: 25220405 [TBL] [Abstract][Full Text] [Related]
19. PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. Nishida T; Yasuda H J Biol Chem; 2002 Nov; 277(44):41311-7. PubMed ID: 12177000 [TBL] [Abstract][Full Text] [Related]
20. SUMO3 modification by PIAS1 modulates androgen receptor cellular distribution and stability. Yang N; Liu S; Qin T; Liu X; Watanabe N; Mayo KH; Li J; Li X Cell Commun Signal; 2019 Nov; 17(1):153. PubMed ID: 31752909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]